Amnestic mild cognitive impairment doubles risk of death

July 16, 2012

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that people with a form of mild cognitive impairment (MCI), a risk factor for developing Alzheimer's disease, have twice the risk of dying compared with cognitively normal people. Those with dementia have three times the risk. The findings are being presented at the Alzheimer's Association International Conference in Vancouver this week.

Amnestic MCI is a condition in which people have more severe than normal for their age and education, but not serious enough to affect daily life. (Another form of MCI, nonamnestic MCI, is characterized by impaired other than memory, such as trouble planning and organizing or poor judgment.) According to the Alzheimer's Association, long-term studies suggest that 10 to 20 percent of people aged 65 and older may have MCI.

Einstein researchers studied 733 individuals enrolled in the Einstein Aging Study. The participants were at least 70-years-old and lived in The Bronx. At the start of the study, each had a cognitive evaluation for baseline and at least one annual follow-up visit. They were also tested for the APOE-4 , which is linked to increased risk for Alzheimer's. Participants were followed for an average of five years (up to a high of 16 years).

Study investigators found that participants with amnestic MCI had more than two times (2.17) greater risk of death. Nonamnestic MCI did not appear to increase . The risk of death among participants with dementia was more than three times greater (3.26) than that of those who were cognitively normal. Researchers also found that having the APOE-4 gene variant, a greater number of co-morbidities, and were also related to higher risk of mortality.

"While there is no treatment for MCI, dementia or Alzheimer's, these findings support the benefits of early detection and monitoring of cognitive impairment in order to prolong life," said Richard Lipton, M.D., the senior author of the study and director of the Einstein Aging Study. Dr. Lipton is also the Edwin S. Lowe Chair in Neurology at Einstein and professor and vice chair of the Saul R. Korey Department of Neurology at Einstein and Montefiore Medical Center, the University Hospital for Einstein.

The Einstein Aging Study examines both normal brain aging and the special challenges of Alzheimer's disease and other dementias. Since its initial funding 30 years ago by the National Institute on Aging (AG003949), part of the National Institutes of Health, its investigators have contributed to the understanding of brain aging by tracking over 2,000 Bronx County residents in order to facilitate earlier diagnosis, prevention and treatment of Alzheimer's disease.

Explore further: Researchers connect gene to pre-Alzheimer's

Related Stories

Researchers connect gene to pre-Alzheimer's

July 19, 2011

(Medical Xpress) -- Cornell scientists have shown a significant correlation for the first time between a human gene and people's risk for mild cognitive impairment (MCI), often a precursor to Alzheimer's disease and related ...

Study: Men at higher risk for mild memory loss than women

January 25, 2012

Men may be at higher risk of experiencing mild cognitive impairment (MCI), or the stage of mild memory loss that occurs between normal aging and dementia, than women, according to a study published in the January 25, 2012, ...

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.